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OBJECTIVES 
CONCLUSIONS 
Background 
Quantitative nephelometric assays detecting polyclonal sheep anti-
sera and serum FLCs (e.g. Freelite®) are the gold standard method 
for monitoring FLC secretion from myeloma cells, but are only 
available in central laboratories. The frequent delay between 
venepuncture and assay results can affect diagnosis, treatment 
decisions and patient communication. Second generation point-of-
care assays have been developed using monoclonal antibodies to 
FLCs, producing results in 10 minutes (e.g. Seralite®). This study 
investigates potential impact on care of patients with plasma cell 
dyscrasias. 
Aims 
• Assess current practice in FLC monitoring 
• Review potential impact of rapidly available point-of-care FLC 
testing 
This retrospective study analysed blood results 
and patient records  from FLC quantification 
request samples sent to the Royal Devon and 
Exeter Hospital over 2 years from October 2012.  
SAMPLE 
• 3,341 FLC requests sent to the RD&E 
• 596 requests included in this study (18%) 
PATIENT DEMOGRAPHICS 
• 83 patients 
• Median age 72 (42-89) 
• Frequent diagnoses: 
• Myeloma 45% 
• MGUS 35% 
• Lymphoplasmacytic Lymphoma 5% 
• 90.3% of samples were from patients with 
known plasma cell dyscrasias 
FLC RESULT SIGNIFICANCE 
• The median time between venepuncture and 
review of results in clinic was 28 days (range 
5-364) 
• 70 FLC results were significantly changed 
compared to the previous result (11.7%) 
• 55 of those altered results coincided with 
significant change in paraprotein or 
deterioration in end-organ function (9.23%) 
CONSULTATIONS 
• A rapidly available SFLC result would have 
changed what the patient was told in 
consultations on 71 occasions (11.9%) 
• This would have affected 34 of the 83 
patients included in this study (40.9%) 
MANAGEMENT 
• Rapidly available results would have altered 
patient management on 21 occasions (3.5% 
of data points) 
• This would have affected the 
      management of 25.3% of patients. 
RESULTS 
METHODS 
A point-of-care assay for serum FLCs would offer benefit in the rapid 
diagnosis and follow-up of patients with plasma cell dyscrasias, 
enabling clinicians to make up-to-date decisions on treatment and 
communication.  
This could reduce patient exposure to ineffective, expensive, toxic 
chemotherapy, whilst allowing rapid prevention of end-organ 
damage in progressive disease 
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